Live Breaking News & Updates on Global cardiovascular

Stay updated with breaking news from Global cardiovascular. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Entrepreneurial cardiologist Dr. Richard Heuser dies at 73

"Renowned cardiologist and medical device innovator, Dr. Richard Heuser, dies at 73 while on Alaskan cruise. His company, PQ Bypass, sold for $ ....

Phoenix , Arizona , United-states , Alaska , Alaskan , Richard-heuser , Arizona-state-university-college-of-health-solutions , University-of-arizona-college-medicine-phoenix , Heart-vascular-center , Cardiologist-richard-heuser , Phoenix-business , Global-cardiovascular

Global Soft Tissue Repair Market size to grow by USD 3.42 billion from 2022-2027 | 3M Co., Acera Surgical Inc., and AlloSource are some leading market companies

/PRNewswire/ The Global Soft Tissue Repair Market size is projected to grow by USD 3.42 billion, accelerating at a CAGR of over 4.5% during the forecast. ....

France , United-kingdom , United-states , Japan , American , America , Jesse-maida , Medtronic-plc , Company-analysis , Acera-surgical-inc , Surgical-inc , Conmed-corp

Global Cardiovascular and Cerebrovascular Diseases Market Research Analysis 2023-2029: Sizeable Cardiovascular Market Shows Slower Growth Amid Patent Expirations and Generics' Rise

/PRNewswire/ The "Global Cardiovascular and Cerebrovascular Diseases Market (2023 Edition): Analysis By Drug Type, By Indication, By Region, By Country:. ....

United-states , China , India , Spain , Italy , France , Germany , United-kingdom , Canada , Japan , Dublin , Ireland

Global Cardiovascular and Cerebrovascular Diseases Market :

Executive Summary. Azoth Analytics has released a research report titled “Cardiovascular and Cerebrovascular Market (2023 Edition)” which provides a. ....

China , United-states , Germany , Canada , United-kingdom , France , New-york , Japan , Spain , India , Italy ,

Novel Agent Offers Hope for Hereditary ATTR Polyneuropathy

The investigational antisense agent eplontersen slows disease progression and im-proves quality of life in hereditary transthyretin-mediated amyloid polyneuropathy, final data from a phase 3 trial indicate. ....

United-states , American , Mina-makar , Sami-khella , University-of-pennsylvania-school-medicine , Astrazeneca , Ionis-pharmaceuticals-astrazeneca , American-academy-of-neurology , Drug-administration , Perelman-school-of-medicine , Perelman-school , Pennsylvania-school